BR9913839A - Preparações farmacêuticas independentes de agitação, de unidades múltiplas, de liberação lenta e processo para sua preparação - Google Patents

Preparações farmacêuticas independentes de agitação, de unidades múltiplas, de liberação lenta e processo para sua preparação

Info

Publication number
BR9913839A
BR9913839A BR9913839-5A BR9913839A BR9913839A BR 9913839 A BR9913839 A BR 9913839A BR 9913839 A BR9913839 A BR 9913839A BR 9913839 A BR9913839 A BR 9913839A
Authority
BR
Brazil
Prior art keywords
slow
preparation
pharmaceutical preparations
unit
release pharmaceutical
Prior art date
Application number
BR9913839-5A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp
Erich Brendel
Claus Weisemann
Ernst Chantraine
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9913839A publication Critical patent/BR9913839A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Nonmetallic Welding Materials (AREA)

Abstract

Patente de Invenção: <B>"PREPARAçõES FARMACêUTICAS INDEPENDENTES DE AGITAçãO, DE UNIDADES MúLTIPLAS, DE LIBERAçãO LENTA E PROCESSO PARA SUA PREPARAçãO<D>. A presente invenção refere-se a formas de dose administrável por via oral de unidades múltiplas, de liberação lenta, tendo liberação independente de agitação controlada de composto ativo, e processo para sua produção utilizando um polímero hidrofílico erodível (HPC) e limitação do tamanho máximo das particulas do polímero contendo o composto ativo a <243> 3 mm.
BR9913839-5A 1998-09-18 1999-09-17 Preparações farmacêuticas independentes de agitação, de unidades múltiplas, de liberação lenta e processo para sua preparação BR9913839A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
PCT/EP1999/006882 WO2000016748A1 (de) 1998-09-18 1999-09-17 Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
BR9913839A true BR9913839A (pt) 2001-06-12

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913839-5A BR9913839A (pt) 1998-09-18 1999-09-17 Preparações farmacêuticas independentes de agitação, de unidades múltiplas, de liberação lenta e processo para sua preparação

Country Status (29)

Country Link
US (1) US6805881B1 (pt)
EP (1) EP1113787B1 (pt)
JP (1) JP2002526437A (pt)
KR (1) KR100660072B1 (pt)
CN (1) CN1178650C (pt)
AT (1) ATE260645T1 (pt)
AU (2) AU5861499A (pt)
BG (1) BG105325A (pt)
BR (1) BR9913839A (pt)
CA (1) CA2344372C (pt)
DE (2) DE19842753A1 (pt)
DK (1) DK1113787T3 (pt)
EE (1) EE04700B1 (pt)
ES (1) ES2215404T3 (pt)
HK (1) HK1040932B (pt)
HR (1) HRP20010198A2 (pt)
HU (1) HUP0103669A3 (pt)
ID (1) ID28735A (pt)
IL (2) IL141532A0 (pt)
NO (1) NO20011211D0 (pt)
NZ (1) NZ510563A (pt)
PL (1) PL195543B1 (pt)
PT (1) PT1113787E (pt)
RU (1) RU2235540C2 (pt)
SK (1) SK285099B6 (pt)
TR (1) TR200100756T2 (pt)
UA (1) UA73097C2 (pt)
WO (2) WO2000016747A1 (pt)
ZA (1) ZA200101485B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE502006009169D1 (en) 2005-10-04 2011-05-05 Bayer Schering Pharma Ag NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
PT2391345E (pt) * 2009-01-28 2014-12-03 Novartis Ag Formulações galénicas compreendendo aliscireno
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
EE04700B1 (et) 2006-10-16
DE59908764D1 (de) 2004-04-08
AU6191899A (en) 2000-04-10
HUP0103669A2 (hu) 2002-01-28
EE200100161A (et) 2002-08-15
WO2000016748A1 (de) 2000-03-30
AU5861499A (en) 2000-04-10
DK1113787T3 (da) 2004-05-17
AU750617B2 (en) 2002-07-25
CN1178650C (zh) 2004-12-08
NO20011211L (no) 2001-03-09
US6805881B1 (en) 2004-10-19
IL141532A (en) 2007-03-08
NZ510563A (en) 2002-10-25
SK285099B6 (sk) 2006-06-01
PT1113787E (pt) 2004-07-30
BG105325A (bg) 2001-11-30
NO20011211D0 (no) 2001-03-09
KR100660072B1 (ko) 2006-12-22
CN1317959A (zh) 2001-10-17
WO2000016747A1 (de) 2000-03-30
CA2344372C (en) 2009-12-22
PL346535A1 (en) 2002-02-11
HK1040932A1 (en) 2002-06-28
TR200100756T2 (tr) 2001-07-23
IL141532A0 (en) 2002-03-10
ZA200101485B (en) 2002-02-22
HUP0103669A3 (en) 2006-07-28
JP2002526437A (ja) 2002-08-20
HRP20010198A2 (en) 2002-04-30
KR20010073172A (ko) 2001-07-31
ID28735A (id) 2001-06-28
ES2215404T3 (es) 2004-10-01
DE19842753A1 (de) 2000-03-23
RU2235540C2 (ru) 2004-09-10
CA2344372A1 (en) 2000-03-30
PL195543B1 (pl) 2007-09-28
EP1113787A1 (de) 2001-07-11
UA73097C2 (en) 2005-06-15
HK1040932B (zh) 2005-08-05
ATE260645T1 (de) 2004-03-15
EP1113787B1 (de) 2004-03-03
SK3722001A3 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
BR9913839A (pt) Preparações farmacêuticas independentes de agitação, de unidades múltiplas, de liberação lenta e processo para sua preparação
BR9908488A (pt) Composição farmacêutica de topiramato
MY124599A (en) Oral suspension of pharmaceutical substance
MA23608A1 (fr) Forme de dosage ii d&#39;unite multiple en comprime
BR9405843A (pt) Processo para reduzir perda óssea e uso de um composto
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
PT93877A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao oral de medicamentos, por exemplo antibioticos beta-lactamicos
MA23170A1 (fr) Procede de preparation d&#39;un nouveau compose .
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
RU2003119545A (ru) Фармацевтические композиции для перорального введения фамакологических действующих веществ
BR9607752A (pt) Formulação farmacêutica de microcápsula de liberação controlada, processo para sua preparação, e, processo de uso das microcápsulas
HUP0402154A2 (hu) Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
HUP0202781A2 (hu) Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk
TNSN03106A1 (fr) Procede pour la production d&#39;une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
PT90816A (pt) Processo para a preparacao de composicoes farmaceuticas contendo analogos de 2&#39;,5&#39;-oligoadenilato
PT1178787E (pt) Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.